Easing swallowability and taste-masking for pediatric and geriatric populations
More than 35% of the general population has serious issues swallowing medicines. Nearly one-quarter of people in long-term care facilities and 45% of elderly institutionalized patients suffer from some form of dysphagia. But age is not the only factor. More than one-third of adolescents ages 11-20 report issues with swallowing tablets.
With the need in the US and Europe to provide pediatric alternatives for new drugs, developers are examining ways to provide a simple alternative for taste-masking and delivery-ones that reduce the complexity of formulation, successfully mask odor and taste, are friendly to use and provide the correct dose every time. Current common approaches such as additives, matrix entrapment, physical barriers and release modulation can create issues through complexity. Capsugel has developed new technologies designed to optimize taste masking and delivery.
Please register for this webinar. If this time does not work for your schedule, you can still register and we will send a link to the on-demand version shortly after the webinar.
Presented by
Matt Richardson, Ph.D.,
Manager, Pharmaceutical Business Development
Matt Richardson is the Manager of Pharmaceutical Business Development at Capsugel. He is a graduate of Wofford College, holds a doctorate in Synthetic Organic Chemistry from Wake Forest University and a post-doctoral appointment at Virginia Tech. Before joining Capsugel he was with SchweizerHall and Irix Pharmaceuticals as a process development Scientist for API synthesis.
Since joining Capsugel in 2005, he has worked with many pharmaceutical and nutraceutical customers to understand the formulation aspects of their products with two-piece hard capsules and has been an invited speaker at numerous seminars and webinars on topics of hard capsules, crosslinking, capsules for use in delayed release, as well as DPI-based inhalation.
Eduardo Jule, Ph.D.,
Director, Pharmaceutical Business Development
Dr. Jule joined Capsugel in 2004 as part of the newly formed Pharmaceutical Business Development team based in Bornem, Belgium, where he supported the expansion of the Colmar and Strasbourg, France based product development operations. In 2010, he relocated to Boston, Massachusetts and returned to Research & Development, supervising lipid-based formulation development, from feasibility to scale-up and manufacturing.
Ed and his team are currently responsible for Business Development in areas ranging from oral bioavailability enhancement to modified and targeted release and other emerging segments such as abuse deterrence, pediatric applications and drug delivery to the lung.
Prior to joining Capsugel, Ed worked for drug delivery firm NanoCarrier (Tokyo, Japan), where he was involved in nanotechnology based drug delivery licensing operations, technology acquisition and pharmaceutical development programs with the industry, the academia and the National Cancer Center. He received his doctoral degree in Materials Science Engineering from the University of Tokyo, where he worked on the design and use of polymeric nanoparticles for cancer and gene therapies.
